This article reviews the use of nitinol endovascular devices and the effects of biomechanics, design, and nitinol processing and microstructural purity on fatigue and fracture. Nitinol self-expanding stents have shown an improvement in the effectiveness of treatment of femoral arterial disease with a restenosis rate as low as 17.9 % and patency rates of more than 85 % at 18 months. Nevertheless, follow-up procedures show stent fracture rates of up to 52 % with some stent designs and nitinol source material. This article will review the improvements in nitinol stent technology due to: (1) better understanding of the in vivo biomechanical deformation dynamics and (2) ingenuity in stent design improvements in the understanding of nitinol fatigue, including effects of thermomechanical processing, prestrain, and “micropurity.”